Calliditas Therapeutics AB ADR (CALT) News
Filter CALT News Items
CALT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CALT News Highlights
- For CALT, its 30 day story count is now at 2.
- Over the past 2 days, the trend for CALT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- AB and CMA are the most mentioned tickers in articles about CALT.
Latest CALT News From Around the Web
Below are the latest news stories about CALLIDITAS THERAPEUTICS AB that investors may wish to consider to help them evaluate CALT as an investment opportunity.
Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathyCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has granted Conditional Marketing Authorization (CMA) for Kinpeygo® for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram. |
Number of shares and votes in Calliditas TherapeuticsDuring January, Calliditas Therapeutics AB (publ) has issued 7,500 common shares connected to the company's long term incentive program 2019/2022. Thus, as of January 31, 2023, the number of shares and votes in the company amounts to 59,580,087 shares and 59,580,087 votes. |
New Strong Sell Stocks for January 6thCALT, CVGW and DFH have been added to the Zacks Rank #5 (Strong Sell) List on January 6, 2023. |
China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA NephropathyCalliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has recommended Priority Review for the New Drug Application (NDA) of Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of rapid disease progression. |
Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2019/2022Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced today that CEO Renée Aguiar-Lucander has net purchased 50,000 shares through Calliditas' warrant program 2019/2022. Following the new subscription for shares, her shareholding in the company will amount to 643,000 common shares. |
Calliditas To Work With Viatris To Bring Nefecon To Japanese PatientsCANONSBURG (dpa-AFX) - Calliditas Therapeutics AB (CALT) has entered into a license agreement with Viatris, through its Global Healthcare Gateway, to bring Nefecon, a specialty IgAN therapy to pat… |
Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in JapanCalliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") announced today that they have entered into an exclusive license agreement with Viatris Pharmaceuticals Japan Inc., a subsidiary of Viatris Inc. (NASDAQ: VTRS) ("Viatris"), to register and commercialize Nefecon, a specialty drug recently approved in Europe and the US for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN) in Japan. |
Calliditas to host fireside chat with its China commercial partner, Everest MedicinesCalliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a fireside chat with its commercial partner Everest Medicines (HKEX 1952.HK, "Everest") on Wednesday, December 14th, 2022 at 8am Eastern Time (2pm Central European Time, 8pm China Standard Time). |
Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPACalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Chinese regulatory authority National Medical Products Administration ("NMPA") has accepted Everest Medicines' (HKEX 1952.HK, "Everest") New Drug Application ("NDA") for Nefecon. The acceptance brings Nefecon, approved and marketed in the U.S. under the name TARPEYO® and in the E.U. as Kinpeygo®, an important step closer to potentially becoming the first-ever approved therapeutic option in |
Calliditas Therapeutics: Interim Report Q3, 2022"On July 15th the European Commission issued the conditional marketing authorization for Kinpeygo, which marked the first time that any drug has achieved approval for this rare disease in EU. We immediately started the process of transferring the market authorization to our European partner, STADA Arzneimittel AG, in order to enable a launch in Europe as quickly as possible. STADA is initially launching the product in Germany, with other European countries to follow over time. |